The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Combination therapy for kidney disease in people with diabetes mellitus
Open accessAbstract
Diabetic kidney disease (DKD), defined as co-existing diabetes and chronic kidney disease in the absence of other clear causes of kidney injury, occurs in approximately 20-40% of patients with diabetes mellitus. As the global prevalence of diabetes has increased, DKD has become highly prevalent and a leading cause of kidney failure, accelerated cardiovascular disease, premature mortality and global health care expenditure. Multiple pathophysiological mechanisms contribute to DKD, and single lifestyle or pharmacological interventions have shown limited efficacy at preserving kidney function. For nearly two decades, renin-angiotensin system inhibitors were the only available kidney-protective drugs. However, several new drug classes, including sodium glucose cotransporter-2 inhibitors, a non-steroidal mineralocorticoid antagonist and a selective endothelin receptor antagonist, have now been demonstrated to improve kidney outcomes in people with type 2 diabetes mellitus. In addition, emerging preclinical and clinical evidence of the kidney-protective effects of glucagon-like-peptide-1 receptor agonists has led to the prospective testing of these agents for DKD. Research and clinical efforts are geared towards using therapies with potentially complementary efficacy in combination to safely halt kidney disease progression. As more kidney-protective drugs become available, the outlook for people living with DKD should improve in the next few decades.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 2×
“…with T2DM, urine albumin ‐ to ‐ creatinine ratio (UACR) ≥300 mg/g or proteinuria ≥0.5 g per day and serum creatinine 1.3–3.0 mg/dl (115–265 μmol/l) showed a 16% reduction in the risk of doubling of serum creatinine and kidney failure in those randomly assigned to losartan versus placebo 9 .”
InfluentialCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394 · cited 2×
“…cardiovascular and kidney protection despite increased RAAS activity is that combined SGLT2 inhibitor and RAS inhibitor treatment activates alternative, non-classic RAAS pathways such as angiotensin 1–7 and Mas 104 , which are associated with anti-fibrotic and anti-inflammatory effects 40 .”
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935 · cited 3×
“…(SGLT2) inhibitors (CREDENCE (canagliflozin), DAPA-CKD (dapagliflozin) and EMPA-KIDNEY (empagliflozin) trials) 15–17 , the non-steroidal mineralocorticoid antagonist (MRA) finerenone (FIDELIO-DKD trial) 18 and the selective endothelin receptor antagonist (ERA) atrasentan (SONAR trial) 19 .”
InfluentialSelf-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754 · cited 1×
“…with sodium glucose cotransporter-2 (SGLT2) inhibitors (CREDENCE (canagliflozin), DAPA-CKD (dapagliflozin) and EMPA-KIDNEY (empagliflozin) trials) 15–17 , the non-steroidal mineralocorticoid antagonist (MRA) finerenone (FIDELIO-DKD trial) 18 and the selective endothelin receptor antagonist (ERA)…”
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Research works printed but not linked: 1
- Bolignano, D., Palmer, S. C., Navaneethan, S. D. & Strippoli, G. F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. 10, CD007004 (2014).
Cited by
Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03133-0 · Cited by 200
“That conclusion is supported by other reviews and meta-analyses 10,11 .”
ResultSelf-citationNdumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 146
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Self-citationDiabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
Bae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 101
Metadata
- Authors
- van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., Tuttle, K., Waikar, S. S., & Heerspink, H. J. L.
- Affiliations
- University of Colorado Anschutz (US)
- University of Toronto (CA)
- University of Padua (IT)
- Joslin Diabetes Center (US)
- Steno Diabetes Center Copenhagen (DK)
- University of Michigan (US)
- University of Washington (US)
- Boston University (US)
- University Medical Center Groningen (NL)
- ORCID
- Venue
- Nature Reviews Nephrology
- Published
- 2024-04-03
- Volume
- 20
- Issue
- 7
- Pages
- 433-446
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W4393871692
- Cited by
- 127
- References
- 148
- Citations by year
- 2026: 55 · 2025: 55 · 2024: 17
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- National Institutes of Health (1ot2od032581-01, OT2OD032581, UL1TR002319)
- Centers for Disease Control and Prevention (75D301-21-P-12254)
- National Institute on Aging (U01AG076789)
- National Heart, Lung, and Blood Institute (R01HL165433, OT2HL161847)
- National Institute of Allergy and Infectious Diseases (UM1AI108568)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK124449, R01DK125084, U54DK083912, R21DK129720, P30DK036836, U01DK130060, U01DK116102, R25DK128858, U24DK114886, R01DK108803, U01DK133092, U01DK100846, R01DK129211)
- National Center for Advancing Translational Sciences
- National Institute on Minority Health and Health Disparities (R01MD014712)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, combination therapy, renin-angiotensin system inhibitors, SGLT2 inhibitors, mineralocorticoid receptor antagonists, endothelin receptor antagonists, GLP-1 receptor agonists, type 2 diabetes, chronic kidney disease, kidney disease progression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Endothelin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination therapy for kidney disease in people with diabetes mellitus. https://app.cochat.ai/papers/10.1038/s41581-024-00827-z
- The paper
- van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., Tuttle, K., Waikar, S. S., & Heerspink, H. J. L. (2024). Combination therapy for kidney disease in people with diabetes mellitus. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-024-00827-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.